Autolus Therapeutics plc, a foreign private issuer voluntarily filing a Form 10-Q, reported 266,340,330 ordinary shares outstanding as of November 9, 2026. The filing highlights the commercialization of AUCATZYL for adult r/r B-ALL and notes a restructuring and workforce reduction plan initiated in April 2026.
Autolus Therapeutics reported Q3 2026 financial results, highlighted by $41.2 million in AUCATZYL net product revenue, a 95% year-over-year increase. The company raised its full-year 2026 revenue guidance for AUCATZYL to meet or exceed $150 million, driven by increased demand and manufacturing efficiencies that improved gross margins to 57%.
“We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium.”
Dr. Christian Itin, Chief Executive Officer
“AUCATZYL’s performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus’ proven manufacturing and commercial capabilities.”